Alimera Sciences, Inc.
NASDAQ:ALIM
5.54 (USD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Alimera Sciences, Inc. |
Symbool | ALIM |
Munteenheid | USD |
Prijs | 5.54 |
Beurswaarde | 301,288,468 |
Dividendpercentage | 0% |
52-weken bereik | 2.606 - 5.65 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Richard S. Eiswirth Jr. |
Website | https://alimerasciences.com |
An error occurred while fetching data.
Over Alimera Sciences, Inc.
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)